Author:
Nicholls K.,Bleasel K.,Becker G.
Publisher
Springer Berlin Heidelberg
Reference7 articles.
1. Barbey F, Livio F (2006) Safety of enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford, Chapter 41.
http://www.ncbi.nlm.nih.gov/books/NBK11617/
2. Eng CM, Guffon N, Wilcox WR et al (2001a) Safety and efficacy of recombinant human α-galactosidase A – replacement therapy in Fabry's disease. N Engl J Med 345:9–16
3. Eng CM, Banikazemi M, Gordon RE et al (2001b) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722
4. Linthorst GE, Hollack CEM, Donker-Koopman WE, Strijland A, Aerts JMFG (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alfa and beta. Kidney Int 66:1589–1595
5. Ramaswami U, Wendt S, Parini R et al (2005) Safety of enzyme replacement therapy with agalsidase alfa in children with Fabry disease. J Inherit Metab Dis 28(Suppl 1):330
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献